As a promising agent for use in cancer therapy, GPER could be a biological target in a wide range of cancer cells, producing positive results as quantified by their growth inhibitory activity, including renal [14], liver [15] and pancreatic [16] cancers. The gene discussed is GPER1; the disease is cancer.